Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Structure Therapeutics Inc. GPCR NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
59/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$116.71
+115.1%

Balance sheet is a point-in-time snapshot. TTM shows the most recent available quarter.

Metric Latest Quarter (2025-12)
Total Assets $1.58B
Total Liabilities $67.54M
Total Debt $6.49M
Cash & Investments $1.45B
Total Stockholders Equity $1.52B

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 MORF
MORF
Morphic Holding, Inc.
$56.99
+0.04%
 IRON
IRON
Disc Medicine, Inc.
$70.18
-0.43%
 DICE
DICE
DICE Therapeutics, Inc.
$47.55
+0.06%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.47
+0.05%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$17.12
+1.18%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 ELDN
ELDN
Eledon Pharmaceuticals, Inc.
$3.30
+3.13%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message